Tarumi K, Yagihashi A, Watanabe N, Kameshima H, Yajima T, Hirata K
Department of Laboratory Diagnosis, Sapporo Medical University School of Medicine, Japan.
Immunopharmacol Immunotoxicol. 1998 May;20(2):211-6. doi: 10.3109/08923979809038540.
Since FK506 binding protein (FKBP12) inhibits dose-dependently the immunosuppressive activity of FK506 in vitro, plasma FKBP12 levels were measured after rat small bowel transplantation (SBTx). The mean plasma FKBP12 level in untreated recipients increased significantly at the onset of acute cellular rejection (ACR) compared to that in FK506-treated recipients without rejection at the same time after SBTx (P < 0.05). In both groups, however, the mean plasma FKBP12 level did not increase at 1 day after SBTx. These results suggest that plasma FKBP levels may be affected by ACR, but not by ischemia-reperfusion injury. Therefore, the plasma FKBP12 level should be considered as one of the parameters related to the immunosuppressive activity of FK506 in SBTx.
由于FK506结合蛋白（FKBP12）在体外可剂量依赖性地抑制FK506的免疫抑制活性，因此在大鼠小肠移植（SBTx）后测定了血浆FKBP12水平。与SBTx后相同时间未发生排斥反应的FK506治疗受体相比，未治疗受体在急性细胞排斥反应（ACR）开始时的平均血浆FKBP12水平显著升高（P < 0.05）。然而，在两组中，SBTx后1天平均血浆FKBP12水平均未升高。这些结果表明，血浆FKBP水平可能受ACR影响，但不受缺血再灌注损伤影响。因此，血浆FKBP12水平应被视为与SBTx中FK506免疫抑制活性相关的参数之一。
